The chorda tympani branch of the facial nerve is the anatomical key to understanding taste loss with facial palsy — taste from the anterior two-thirds of the tongue is carried by the chorda tympani (a branch of the facial nerve CN VII), which travels through the middle ear before joining the lingual nerve. In Bell's palsy (idiopathic facial nerve inflammation), the entire facial nerve is affected, including the chorda tympani branch, causing: ipsilateral taste loss from the anterior tongue + ipsilateral loss of lacrimation (greater petrosal nerve) + hyperacusis (nerve to stapedius). The patient may not volunteer taste loss unless specifically asked — 'Have you noticed any change in how food tastes?' should be a routine question in any facial palsy assessment. Ramsay Hunt syndrome (herpes zoster oticus) involves the geniculate ganglion of the facial nerve and typically causes: severe otalgia (ear pain, often the first symptom) + ipsilateral facial palsy + vesicles in the external ear canal/auricle (sometimes on the soft palate) + sensorineural hearing loss + vertigo. It has a significantly worse prognosis than Bell's palsy (complete recovery in only approximately 50–70% with antiviral + steroid treatment, vs 85% for Bell's palsy with steroids alone). Prompt treatment (within 72 hours) with both aciclovir AND prednisolone is essential.

Drug-induced dysgeusia is far more common than most clinicians appreciate — it affects approximately 11% of patients taking drugs that cause taste disturbance, and for many of these patients the taste change is the most bothersome side effect of their medication. The mechanism varies by drug: (1) drugs excreted in saliva affect taste directly at the receptor level (metronidazole, metformin — both achieve high salivary concentrations, producing a persistent metallic taste); (2) drugs that chelate zinc impair taste receptor function (captopril, penicillamine — zinc is essential for carbonic anhydrase VI in taste buds); (3) drugs that reduce salivary flow (anticholinergics, antihistamines, antidepressants) cause dry mouth → altered taste by reducing the aqueous medium for taste molecule delivery to receptors. The practical management: if a patient complains of metallic or bitter taste and is taking any of the listed drugs, consider stopping the drug (if clinically appropriate) or switching to an alternative. If zinc-chelating drugs are necessary, zinc supplementation (zinc sulphate 45 mg/day, taken away from the chelating drug) may partially compensate.

Serum zinc testing for taste disorders is one of the most underperformed useful investigations in primary care — zinc deficiency is a common and entirely reversible cause of hypogeusia and dysgeusia, particularly in: elderly patients (reduced dietary intake + reduced absorption), patients taking zinc-chelating drugs (penicillamine, captopril, tetracycline), vegetarians and vegans (plant phytates inhibit zinc absorption), patients with malabsorption (coeliac, IBD, short bowel syndrome), and patients on long-term PPI therapy (PPIs reduce zinc absorption by approximately 30%). Normal serum zinc: 10.7–17.5 μmol/L. Levels below 10.7 μmol/L indicate zinc deficiency. Treatment: zinc sulphate 45 mg (elemental zinc 10 mg) OD or TDS with food (to reduce GI side effects). Taste improvement is expected within 4–8 weeks of zinc repletion if deficiency was the cause. The copper depletion risk with high-dose zinc supplementation (zinc competitively inhibits copper absorption) means that long-term high-dose zinc should be accompanied by copper monitoring.

Parosmia is one of the most distressing sequelae of COVID-19 olfactory damage — it is a distorted smell perception where familiar odours are perceived as disgusting (coffee smelling like petrol, meat smelling like rotting, or sweet foods smelling like chemicals). Parosmia affects approximately 10–15% of people with persistent post-COVID smell dysfunction and is characterised by: onset several weeks after the acute infection (rather than at the same time); worsening with strong smells; specific trigger foods or household smells; and profound impact on quality of life, appetite, and mental health. Paradoxically, parosmia is a positive prognostic sign — it indicates that olfactory nerve fibres are regenerating (misrouted regenerating axons interpret incoming signals incorrectly, creating the distorted perception). Most patients with parosmia eventually recover, though the timeline is months to years. The management: continue olfactory training (evidence suggests it accelerates parosmia resolution), avoid major trigger foods temporarily (adapt diet around the parosmia without eliminating all food groups — dietitian referral if severe weight loss), and address the psychological impact (anxiety and depression are extremely common — PHQ-9 and GAD-7, IAPT referral).

Burning mouth syndrome (BMS) is a condition closely associated with taste disorders that is frequently misdiagnosed or dismissed — it affects primarily peri- and post-menopausal women and is characterised by: chronic burning sensation in the mouth (tongue, lips, palate) without visible lesions, often accompanied by altered taste (metallic, bitter) and dry mouth sensation. The condition is idiopathic in most cases (Type 1 — related to altered pain processing) but can be secondary to: nutritional deficiency (iron, B12, zinc, folate), dry mouth (Sjögren's, anticholinergics), oral candidiasis, contact hypersensitivity (dental materials), or psychosocial factors (anxiety, depression). Treatment: for primary BMS — clonazepam oral rinse (0.5 mg clonazepam dissolved in 5 ml water, rinse for 3 min × TDS — off-label but evidence-based), cognitive behavioural therapy, low-dose TCAs (amitriptyline 10–25 mg nocte for central sensitisation). The intensity of BMS symptoms shows a characteristic daily pattern: absent on waking, builds throughout the day, worst in the evening.

The olfactory training protocol (smell training) for post-viral anosmia has the strongest evidence base of any treatment for post-infectious smell/taste loss — a systematic review of 12 RCTs (Pekala et al. 2016) showed that olfactory training significantly improved smell function compared to controls, with benefit evident at 16 weeks and maintained at 56 weeks. The mechanism is neuroplasticity — repeated activation of olfactory neural pathways stimulates axonal regeneration and cortical reorganisation of olfactory processing areas. The original Hummel protocol (2009) used 4 scents representing the 4 odour categories in the Henning odour prism (flowery, fruity, resinous, putrid), sniffed for 20 seconds per odour, twice daily. Subsequent research (Altundag 2015) showed that 'modified' smell training — changing the 4 scents every 12 weeks — was more effective than using the same 4 scents continuously, suggesting that novel stimulation promotes greater neural reorganisation. Patient motivation and adherence are the main determinants of response — the intervention requires consistent daily practice for at least 12 weeks. The AbScent charity website (abscent.org) provides downloadable smell training guides, community forums, and advice on managing parosmia.

Anticholinergic burden and xerostomia is a critically important interaction in elderly patients — anticholinergic drugs (tricyclic antidepressants, oxybutynin, tolterodine, solifenacin, diphenhydramine, chlorphenamine, procyclidine, hyoscine, first-generation antihistamines) suppress parasympathetic stimulation of salivary glands, causing dry mouth and the associated taste impairment. In elderly patients with polypharmacy, the cumulative anticholinergic burden can be substantial — the Anticholinergic Cognitive Burden (ACB) score quantifies this. High ACB scores are associated not only with dry mouth and constipation, but also with cognitive impairment, falls, and urinary retention. GPs who identify taste disorder + dry mouth in an elderly patient should specifically calculate the anticholinergic burden of their medication list and consider whether any anticholinergic drugs can be stopped or substituted with lower-anticholinergic alternatives. The STOPP criteria specifically identify: antidepressants with anticholinergic properties, bladder antimuscarinic drugs for overactive bladder, and first-generation antihistamines as potentially inappropriate in older adults.

The AbScent charity (abscent.org) has become the leading UK resource for post-viral smell and taste disorders — founded by a chemosensory scientist who herself experienced post-viral anosmia, AbScent provides: freely downloadable smell training kits and protocols, a large peer support community forum (particularly valuable for parosmia patients who feel isolated and misunderstood), evidence-based medical information for both patients and clinicians, and advocacy for better clinical recognition and research funding for olfactory disorders. The Fifth Sense charity (fifthsense.org.uk) similarly provides support and resources for smell and taste disorder patients. GPs should routinely signpost post-COVID and post-viral taste/smell disorder patients to these resources — the combination of professional support from the GP (olfactory training prescription, mental health assessment) and community support from these charities significantly improves patient wellbeing and treatment adherence.

The incomplete Bell's palsy recovery threshold for neurology referral is clinically important — the majority of Bell's palsy patients (approximately 70–85%) achieve complete or near-complete recovery with prednisolone treatment within 3–6 months. However, approximately 15–30% have incomplete recovery, and some develop: synkinesis (involuntary facial movements linked to intentional movements, caused by aberrant nerve regeneration — e.g., eye closes when smiling), hemifacial spasm, or crocodile tears (lacrimation when eating). Patients with incomplete recovery at 3 months benefit from: electromyography (EMG) to assess nerve regeneration progress, specialist physiotherapy for facial rehabilitation exercises, and in selected cases — surgical decompression (limited evidence but considered for severe cases with minimal EMG activity at 3 months). Botulinum toxin injections are highly effective for treating synkinesis (specialist facial rehabilitation programmes). The GP should ensure these patients have neurology follow-up arranged rather than being discharged with incomplete recovery.